Comparison of gadobenate dimeglumine with gadopentetate dimeglumine for magnetic resonance imaging of liver tumors

Ryohei Kuwatsuru, Masumi Kadoya, Kuni Ohtomo, Akihiro Tanimoto, Shinji Hirohashi, Takamichi Murakami, Yutaka Tanaka, Kohki Yoshikawa, Hitoshi Katayama

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

RATIONALE AND OBJECTIVES. To compare gadobenate dimeglumine (Gd-BOPTA) with gadopentetate dimeglumine (Gd-DTPA) for magnetic resonance imaging of the liver. METHODS. The contrast agent Gd-BOPTA or Gd-DTPA was administered at a dose of 0.1 mmol/kg to 257 patients suspected of having malignant liver tumors. Dynamic phase images, spin-echo images obtained within 10 minutes of injection, and delayed images obtained 40 to 120 minutes after injection were acquired. All postcontrast images were compared with unenhanced T1-weighted and T2-weighted images obtained immediately before injection. A full safety assessment was performed. RESULTS. The contrast efficacy for dynamic phase imaging was moderately or markedly improved in 90.9% (110/121) and 87.9% (109/124) of patients for Gd-BOPTA and Gd-DTPA, respectively. At 40 to 120 minutes after injection, the corresponding improvements were 21.7% (26/120) and 11.6% (14/121) for spin-echo sequences and 44.5% (53/119) and 19.0% (23/121) for breath-hold gradient-echo sequences, respectively. The differences at 40 to 120 minutes after injection were statistically significant (P < 0.02). Increased information at 40 to 120 minutes after injection compared with information acquired within 10 minutes of injection was available for 24.0% (29/121) of patients with Gd-BOPTA and for 14.5% (18/124) of patients with Gd-DTPA (P < 0.03). Adverse events were seen in 4.7% (6/128) and 1.6% (2/127) of patients receiving Gd-BOPTA and Gd-DTPA, respectively. The difference was not statistically significant. CONCLUSIONS. The efficacy of Gd-BOPTA is equivalent to that of Gd-DTPA for liver imaging during the dynamic phase and superior during the delayed (40-120 minutes) phase of contrast enhancement. Both agents are safe for use in magnetic resonance imaging of the liver.

Original languageEnglish
Pages (from-to)632-641
Number of pages10
JournalInvestigative Radiology
Volume36
Issue number11
DOIs
Publication statusPublished - 2001

Fingerprint

Gadolinium DTPA
Magnetic Resonance Imaging
Injections
Liver
Neoplasms
gadobenic acid
Contrast Media
Safety

Keywords

  • Gadobenate dimeglumine
  • Gadolinium
  • Gadopentetate dimeglumine
  • Liver
  • Magnetic resonance contrast media
  • Magnetic resonance imaging

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Comparison of gadobenate dimeglumine with gadopentetate dimeglumine for magnetic resonance imaging of liver tumors. / Kuwatsuru, Ryohei; Kadoya, Masumi; Ohtomo, Kuni; Tanimoto, Akihiro; Hirohashi, Shinji; Murakami, Takamichi; Tanaka, Yutaka; Yoshikawa, Kohki; Katayama, Hitoshi.

In: Investigative Radiology, Vol. 36, No. 11, 2001, p. 632-641.

Research output: Contribution to journalArticle

Kuwatsuru, R, Kadoya, M, Ohtomo, K, Tanimoto, A, Hirohashi, S, Murakami, T, Tanaka, Y, Yoshikawa, K & Katayama, H 2001, 'Comparison of gadobenate dimeglumine with gadopentetate dimeglumine for magnetic resonance imaging of liver tumors', Investigative Radiology, vol. 36, no. 11, pp. 632-641. https://doi.org/10.1097/00004424-200111000-00002
Kuwatsuru, Ryohei ; Kadoya, Masumi ; Ohtomo, Kuni ; Tanimoto, Akihiro ; Hirohashi, Shinji ; Murakami, Takamichi ; Tanaka, Yutaka ; Yoshikawa, Kohki ; Katayama, Hitoshi. / Comparison of gadobenate dimeglumine with gadopentetate dimeglumine for magnetic resonance imaging of liver tumors. In: Investigative Radiology. 2001 ; Vol. 36, No. 11. pp. 632-641.
@article{d3434321ab4e4261a94c66997c7c98a5,
title = "Comparison of gadobenate dimeglumine with gadopentetate dimeglumine for magnetic resonance imaging of liver tumors",
abstract = "RATIONALE AND OBJECTIVES. To compare gadobenate dimeglumine (Gd-BOPTA) with gadopentetate dimeglumine (Gd-DTPA) for magnetic resonance imaging of the liver. METHODS. The contrast agent Gd-BOPTA or Gd-DTPA was administered at a dose of 0.1 mmol/kg to 257 patients suspected of having malignant liver tumors. Dynamic phase images, spin-echo images obtained within 10 minutes of injection, and delayed images obtained 40 to 120 minutes after injection were acquired. All postcontrast images were compared with unenhanced T1-weighted and T2-weighted images obtained immediately before injection. A full safety assessment was performed. RESULTS. The contrast efficacy for dynamic phase imaging was moderately or markedly improved in 90.9{\%} (110/121) and 87.9{\%} (109/124) of patients for Gd-BOPTA and Gd-DTPA, respectively. At 40 to 120 minutes after injection, the corresponding improvements were 21.7{\%} (26/120) and 11.6{\%} (14/121) for spin-echo sequences and 44.5{\%} (53/119) and 19.0{\%} (23/121) for breath-hold gradient-echo sequences, respectively. The differences at 40 to 120 minutes after injection were statistically significant (P < 0.02). Increased information at 40 to 120 minutes after injection compared with information acquired within 10 minutes of injection was available for 24.0{\%} (29/121) of patients with Gd-BOPTA and for 14.5{\%} (18/124) of patients with Gd-DTPA (P < 0.03). Adverse events were seen in 4.7{\%} (6/128) and 1.6{\%} (2/127) of patients receiving Gd-BOPTA and Gd-DTPA, respectively. The difference was not statistically significant. CONCLUSIONS. The efficacy of Gd-BOPTA is equivalent to that of Gd-DTPA for liver imaging during the dynamic phase and superior during the delayed (40-120 minutes) phase of contrast enhancement. Both agents are safe for use in magnetic resonance imaging of the liver.",
keywords = "Gadobenate dimeglumine, Gadolinium, Gadopentetate dimeglumine, Liver, Magnetic resonance contrast media, Magnetic resonance imaging",
author = "Ryohei Kuwatsuru and Masumi Kadoya and Kuni Ohtomo and Akihiro Tanimoto and Shinji Hirohashi and Takamichi Murakami and Yutaka Tanaka and Kohki Yoshikawa and Hitoshi Katayama",
year = "2001",
doi = "10.1097/00004424-200111000-00002",
language = "English",
volume = "36",
pages = "632--641",
journal = "Investigative Radiology",
issn = "0020-9996",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Comparison of gadobenate dimeglumine with gadopentetate dimeglumine for magnetic resonance imaging of liver tumors

AU - Kuwatsuru, Ryohei

AU - Kadoya, Masumi

AU - Ohtomo, Kuni

AU - Tanimoto, Akihiro

AU - Hirohashi, Shinji

AU - Murakami, Takamichi

AU - Tanaka, Yutaka

AU - Yoshikawa, Kohki

AU - Katayama, Hitoshi

PY - 2001

Y1 - 2001

N2 - RATIONALE AND OBJECTIVES. To compare gadobenate dimeglumine (Gd-BOPTA) with gadopentetate dimeglumine (Gd-DTPA) for magnetic resonance imaging of the liver. METHODS. The contrast agent Gd-BOPTA or Gd-DTPA was administered at a dose of 0.1 mmol/kg to 257 patients suspected of having malignant liver tumors. Dynamic phase images, spin-echo images obtained within 10 minutes of injection, and delayed images obtained 40 to 120 minutes after injection were acquired. All postcontrast images were compared with unenhanced T1-weighted and T2-weighted images obtained immediately before injection. A full safety assessment was performed. RESULTS. The contrast efficacy for dynamic phase imaging was moderately or markedly improved in 90.9% (110/121) and 87.9% (109/124) of patients for Gd-BOPTA and Gd-DTPA, respectively. At 40 to 120 minutes after injection, the corresponding improvements were 21.7% (26/120) and 11.6% (14/121) for spin-echo sequences and 44.5% (53/119) and 19.0% (23/121) for breath-hold gradient-echo sequences, respectively. The differences at 40 to 120 minutes after injection were statistically significant (P < 0.02). Increased information at 40 to 120 minutes after injection compared with information acquired within 10 minutes of injection was available for 24.0% (29/121) of patients with Gd-BOPTA and for 14.5% (18/124) of patients with Gd-DTPA (P < 0.03). Adverse events were seen in 4.7% (6/128) and 1.6% (2/127) of patients receiving Gd-BOPTA and Gd-DTPA, respectively. The difference was not statistically significant. CONCLUSIONS. The efficacy of Gd-BOPTA is equivalent to that of Gd-DTPA for liver imaging during the dynamic phase and superior during the delayed (40-120 minutes) phase of contrast enhancement. Both agents are safe for use in magnetic resonance imaging of the liver.

AB - RATIONALE AND OBJECTIVES. To compare gadobenate dimeglumine (Gd-BOPTA) with gadopentetate dimeglumine (Gd-DTPA) for magnetic resonance imaging of the liver. METHODS. The contrast agent Gd-BOPTA or Gd-DTPA was administered at a dose of 0.1 mmol/kg to 257 patients suspected of having malignant liver tumors. Dynamic phase images, spin-echo images obtained within 10 minutes of injection, and delayed images obtained 40 to 120 minutes after injection were acquired. All postcontrast images were compared with unenhanced T1-weighted and T2-weighted images obtained immediately before injection. A full safety assessment was performed. RESULTS. The contrast efficacy for dynamic phase imaging was moderately or markedly improved in 90.9% (110/121) and 87.9% (109/124) of patients for Gd-BOPTA and Gd-DTPA, respectively. At 40 to 120 minutes after injection, the corresponding improvements were 21.7% (26/120) and 11.6% (14/121) for spin-echo sequences and 44.5% (53/119) and 19.0% (23/121) for breath-hold gradient-echo sequences, respectively. The differences at 40 to 120 minutes after injection were statistically significant (P < 0.02). Increased information at 40 to 120 minutes after injection compared with information acquired within 10 minutes of injection was available for 24.0% (29/121) of patients with Gd-BOPTA and for 14.5% (18/124) of patients with Gd-DTPA (P < 0.03). Adverse events were seen in 4.7% (6/128) and 1.6% (2/127) of patients receiving Gd-BOPTA and Gd-DTPA, respectively. The difference was not statistically significant. CONCLUSIONS. The efficacy of Gd-BOPTA is equivalent to that of Gd-DTPA for liver imaging during the dynamic phase and superior during the delayed (40-120 minutes) phase of contrast enhancement. Both agents are safe for use in magnetic resonance imaging of the liver.

KW - Gadobenate dimeglumine

KW - Gadolinium

KW - Gadopentetate dimeglumine

KW - Liver

KW - Magnetic resonance contrast media

KW - Magnetic resonance imaging

UR - http://www.scopus.com/inward/record.url?scp=0034757441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034757441&partnerID=8YFLogxK

U2 - 10.1097/00004424-200111000-00002

DO - 10.1097/00004424-200111000-00002

M3 - Article

C2 - 11606840

AN - SCOPUS:0034757441

VL - 36

SP - 632

EP - 641

JO - Investigative Radiology

JF - Investigative Radiology

SN - 0020-9996

IS - 11

ER -